Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sona Nanotech Inc C.SONA

Alternate Symbol(s):  SNANF

Sona Nanotech Inc. is a nanotechnology life sciences company, which is engaged in developing targeted hyperthermia therapy. The Company has developed multiple methods for the manufacturing of various types of gold nanoparticles (GNR). It is engaged in research and development of its technology for use in multiplex diagnostic testing platforms and advanced biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of cetyltrimethylammonium bromide (CTAB), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company is focused on the development of a pre-clinical nanomedical therapy for the treatment of cancer using its biocompatible GNR.


CSE:SONA - Post by User

Bullboard Posts
Comment by wallpaper2on Aug 06, 2020 3:51pm
320 Views
Post# 31375177

RE:RE:This is not good news at all.

RE:RE:This is not good news at all.
The news announcement said "Diagnostic Companies sign new agreement to address limitations
in development of POC lateral flow tests." They mentioned they were now dealing with the "Ethics Review Board" and FDA guidelines which were likely going against them.
It sounds like Sona is challenging the results and by doing this they can DELAY posting the results of the field trials. They BOUGHT themselves another 2 weeks to try and produce better % numbers.
That is my take on things and I hope they can solve their problems and produce a kit that gives them the % they require for approval. 
Bullboard Posts